3 H]glucose, tissue uptake averaged 98 Ϯ 3 and 107 Ϯ 4% of infusion, respectively, and was equally divided between glycolysis ( 3 H2O production) and storage (uptake-glycolysis). Glucose oxidation ( 14 CO2), total carbohydrate oxidation (indirect calorimetry), and net carbohydrate balance were also similar, but the thermic effect of glucose was significantly greater after id infusion. Because insulin and estimated portal vein glucose levels were similar during the final 80 min of both infusions, our results suggest that hepatic glucose storage (and therefore muscle storage estimated as whole body minus liver storage) is not affected by the route of glucose administration.
intestinal glucose absorption; glucose storage; glycolysis; thermic effect of glucose ORAL GLUCOSE IS KNOWN TO INDUCE a smaller glycemic and a greater insulinemic response than the same dose given intravenously (24, 26) . These differences and other potential factors specifically related to the site of entry of glucose (6, 18) might influence its metabolic handling by the organism, especially as regards the relative importance of splanchnic vs. peripheral glucose uptake and storage.
Only a few studies have addressed this question in humans using either hepatic vein catheterization or tracer methodology, with discordant results (7, 28, 29) . Among several methodological difficulties encountered when comparing oral and intravenous (iv) glucose metabolism is the difficulty of measuring intestinal absorption without access to the portal vein. Another difficulty is that intestinal absorption is unsteady and poorly predictable, owing to the fluctuations in gastric emptying. For these two reasons it is difficult to obtain a perfect match between an iv infusion and the intestinal absorption of an oral glucose load for comparative studies in the same subject.
To obviate some of these difficulties, the present study aimed at comparing intraduodenal (id) and iv glucose administration in the same individual. Radioisotope techniques were used in a two-step procedure. In a first series of id and iv experiments, we used [2- 3 H]glucose in the infusate to determine the effective pool volume through which glucose is distributed after intestinal absorption as well as the kinetics of this absorption. After measuring these parameters, we compared, in a second series of experiments, the whole body metabolism of id and iv glucose labeled with [3- 3 H]-and [U- 14 C]glucose to measure the rates of tissue uptake, glycolysis, storage, and oxidation of exogenous glucose for the two infusion routes. Total carbohydrate oxidation, net carbohydrate balance, fat oxidation, and energy expenditure were also determined, using indirect calorimetry.
MATERIALS AND METHODS

Protocol
Fourteen healthy male volunteers without history of diabetes participated in the study. Their characteristics were the following: age 27 Ϯ 1 yr, body weight 77 Ϯ 3 kg, and body mass index 22.2 Ϯ 1.6 kg/m 2 . The nature, purpose, and potential risks of the study were explained to the subjects, and their written, informed consent was obtained before participation. The protocol was approved by the Ethics Committee of the Faculty of Medicine of the University of Brussels. Subjects were divided into two groups, as follows.
Group I. Seven subjects participated in this protocol. They were tested with id and iv glucose in random order at a 3-wk interval. At about 6:00 PM on the day before the first experiment, the volunteers were injected with 20 Ci of 3 H2O to determine total body water (TBW) volume from the 3 H2O concentration of basal urine and blood samples collected the next morning. The id test was performed as follows. After an overnight fast of 12 h, an esogastroduodenoscopy was performed using a G1F160 gastroscope (Olympus, Tokyo, Japan) to introduce a "pigtail" 6 French nasoduodenal drainage catheter (Cook Ireland, Limerick, Ireland), whose tip was placed in the duodenum ϳ15 cm beyond the pylorus. Correct catheter positioning was confirmed fluoroscopically. The proximal end of the catheter was then passed through the nasal fossae and secured with tape on the skin next to the nostrils. The whole procedure was performed under mild sedation with 2-3 mg iv of Midazolam (Dormicum, Hoffman-La Roche, Grenzach, Germany) and lasted for ϳ20 min. A small catheter for blood sampling was placed in a dorsal hand vein in a retrograde fashion. This catheter was kept patent with a slow saline drip, and the hand was placed in a temperature-regulated heating pad to allow arterialization of the venous blood. After a resting period of ϳ1 h, two basal blood samples were collected at a 20-min interval. Next, a 20% glucose solution labeled with [2- 3 H]glucose (1.1 Ci/min) and containing 150 mmol NaCl/l to facilitate active intestinal glucose transport (25) was started and infused at a constant rate of 6 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 by use of a peristaltic pump. No priming dose was used. Three milliliters were allowed to flow before time 0 to fill the nasoduodenal catheter. Blood samples for determination of [ 3 H]glucose, 3 H2O, insulin, glucagon, and various substrates were obtained at 20-min intervals until 40 min after the end of infusion. Timed urine specimens were obtained before and after the glucose infusion. The iv infusion test was performed according to the same protocol, except that the infused glucose did not contain NaCl and was administered through an indwelling Teflon catheter located in an antecubital vein.
Group II. Seven subjects participated in this second protocol, which was identical to that of group I except for the following modifications. 1) The infused glucose was labeled with both H]-(1.1 Ci/min) and [U-
14 C]glucose (0.03 Ci/min); and 2) samples of expired air were collected in a rubber bag at 20-min intervals during the infusion and postinfusion periods for prompt analysis of 14 CO2 specific activity. Respiratory gas exchanges were determined by computerized open-circuit calorimetry (Deltatrac, Datex, Helsinki, Finland) during the basal period and for 15-min periods during the intervals between blood sampling. Subjects were asked to make sure that the meal taken the night before each test was similar in quantity and composition and was ingested at the same hour to ensure comparable nutritional conditions.
All tracers used in both groups were purchased from Du Pont-NEN (Boston, MA)
Analytical Procedures
Blood samples were collected in heparinized syringes and transferred to tubes kept on ice. The samples used to measure unlabeled and labeled glucose and lactate concentrations contained NaF, and those used to measure the glucagon concentration contained aprotinin. After centrifugation at 4°C, plasma was stored at Ϫ20°C until assay. Plasma glucose was determined by a glucose oxidase method (Test Combination Glucose; Boehringer Mannheim, Mannheim, Germany 14 CO2 specific activity in expired air was determined as described previously (14) . All determinations were made in duplicate.
Calculations for Group I: Experiments with [2-3 H]Glucose
Tissue uptake of exogenous glucose. Assuming that the glucose taken up by the cells is immediately phosphorylated to glucose 6-phosphate, which is rapidly and reversibly converted to fructose 6-phosphate, the formation of 3 H2O during infusion of [2- 3 H]glucose reflects the exogenous glucose uptake (30) , which was calculated as follows in both id and iv experiments
where GU is the cumulative glucose uptake in grams at time t,
3
H2Oconc is the concentration (in dpm/ml) plasma water at time t, and SAinf is the specific activity of infused glucose (dpm/g).
Effective glucose space during the course of iv glucose infusions. In the iv experiments, the infused glucose enters the bloodstream directly, and at any time, the amount of glucose not taken up by the cells is distributed through an effective extracellular glucose space that can be calculated as
where Veff is the effective volume of the extracellular glucose space at time t, expressed as a fraction of TBW; I is the rate of [2- Intestinal absorption. Assuming that the time course of Veff was comparable in the id and iv experiments in a given subject (see DISCUSSION) , cumulative intestinal glucose absorption (GA) at time t (in g) was calculated as the sum of the extracellular glucose content of exogenous origin at time t and the cumulative amount of glucose taken up by the tissues from time 0 to time t
Calculations for Group II: Experiments with [3-3 H]Glucose
Pathways of glucose metabolism during id and iv glucose infusions. For calculations, we used two items of information obtained in the experiments with group I: 1) the average evolution of V eff with time and 2) the demonstration (see RESULTS) that it takes only ϳ20 min of constant id infusion for absorption to occur at the rate of infusion. Because in the experiments with group II the 3 H label was on carbon-3, the generation of 3 H2O allowed the quantification of glycolysis (30) .
The cumulative uptake and disposal of exogenous glucose in the id and iv experiments at time t were calculated, in grams, according to the following equations (abbreviations as in Eqs. 1 and 2)
For the initial 20 min of the id experiments, I was multiplied by 0.52 to account for incomplete intestinal absorption during this period (see RESULTS) glycolysis
Note that this glycogen synthesis corresponds only to the net amount of glycogen formed by the direct pathway (glucose 3 glucose 1-phosphate 3 glycogen) in muscle and liver. It does not include the glycogen formed in liver through the indirect pathway, because this pathway involves the degradation of glucose into C 3 derivatives, followed by its resynthesis by gluconeogenesis, and is therefore computed as glycolysis. Oxidation of the exogenous glucose integrated over the 3-h infusion period was calculated as
where GO is glucose oxidation expressed in grams per 180 min, CO 2 SA is the specific activity of expired CO2 in disintegrations per minute per milliliter, V CO2 is that measured by the Deltatrac Monitor and expressed in milliliters per minute, and 14 C SAinf is the 14 C specific activity of infused glucose (dpm/g). Corrections for incomplete recovery of respiratory 14 CO2 were made using a correcting factor of 0.54, as suggested by Schneiter et al. (32) .
Carbohydrate and lipid oxidation and energy expenditure were determined from V CO2, V O2, and urinary nitrogen output (15) . The thermic effect of glucose was calculated for the 3-h infusion period as the integrated increment of energy expenditure above baseline value. Net carbohydrate balance was calculated as the difference between tissue glucose uptake and carbohydrate oxidation, measured by indirect calorimetry.
The metabolic fluxes obtained in cumulative form from Eqs. 1 and 3-6 were also calculated for the successive 20-min periods from the differences between the values obtained at two consecutive time points.
Statistical Analysis
Data were expressed as means Ϯ SE. Statistical analysis was performed using the computer program SUPERANOVA (Abacus Concepts, Berkeley, CA). Results were analyzed using a two-factor (group ϫ time) ANOVA with repeated measures on time, and whenever a difference was detected at a statistically significant level (P Ͻ 0.05), simultaneous pairwise comparisons between id and iv tests were made by a modified t-test with the standard error derived from the ANOVA.
RESULTS
Experiments with [2-3 H]Glucose
As shown in Fig. 1A , the radiolabeled glucose concentrations (and therefore the exogenous glucose plasma levels) were significantly lower after id than after iv glucose throughout the infusion period (P ϭ 0.002) and decreased rapidly thereafter in both protocols.
The curves depicting the 3 H 2 O concentration (Fig.  1B) and the cumulative uptakes of exogenous glucose (Eq. 1 and Fig. 2A) were not significantly different in id and iv experiments (P Ͼ 0.05). As shown in Fig. 2B , noncumulative tissue uptake rose faster in the id studies during the initial 80 min, obviously due to the smaller increase in the [ 3 H]glucose concentration (Fig.  1A) . During the last hour of infusion, the uptake/ infusion ratios were fairly steady and averaged 1.06 Ϯ 0.04 and 1.08 Ϯ 0.04, respectively (not significantly different from 1.00), in id and iv studies (Fig. 2B) . Figure 2C shows that the V eff determined from the iv infusion data (Eq. 2) constituted 18 Ϯ 1% of the TBW at t ϭ 20 min and rose gradually to reach a steady-state proportion of 29 Ϯ 3% of the TBW during the last 40 min of infusion. The introduction of the successive individual V eff values in Eq. 3 allowed us to calculate cumulative intestinal glucose absorption in the id experiments (Fig. 2D) , which showed that 99 Ϯ 2% of the infused glucose had been absorbed by the end of 180 min of infusion. Splitting up this curve to provide the time course of absorption per 20-min period (Fig. 2E ) revealed that the absorption rate amounted to only 52 Ϯ 5% of the infusion rate during the initial 20-min period but that, during the following 160 min, the absorption rate rose quickly to slightly, but not significantly, more than the rate of infusion, with an absorption/infusion ratio averaging 1.05 Ϯ 0.03.
Experiments with [3- 3 H]Glucose Table 1 shows that the basal metabolic characteristics of the subjects were comparable at the start of the id and iv infusion tests.
Substrate and hormone concentrations. Total and exogenous glucose concentrations exhibited a biphasic pattern during both iv and id glucose infusion (Fig. 3) . However, peak total glucose levels were lower during id than during iv infusion (153 Ϯ 9 vs. 209 Ϯ 13 mg/dl; P Ͻ 0.005) and occurred significantly earlier (60 Ϯ 7 vs. 80 Ϯ 9 min; P Ͻ 0.02) after the start of infusion. Mean glycemia over 3 h was also significantly reduced (132 Ϯ 4 vs. 178 Ϯ 11 mg/dl; P Ͻ 0.005). After the 180 min of infusion, the glucose concentration dropped rapidly, so that plasma glucose fell to below baseline after 20 and 40 min in both conditions (Fig. 3) . Insulin rose sharply during id glucose infusion, peaked at 40 min, and then declined slowly. The response to iv glucose was more gradual, peaking only at ϳ120 min. Average insulin levels were significantly higher with id glucose over the initial 80 min of infusion (P Ͻ 0.005) but were not different thereafter. Lactate concentrations changed in parallel with glucose concentrations. Peak levels were slightly, but not significantly, higher after id glucose (1.51 Ϯ 0.06 vs. 1.35 Ϯ 0.11 mmol/l; P Ͼ 0.05). Free fatty acid profiles were similar with both types of infusion (Fig. 3) ; an 80% drop was observed during the initial 100 min, followed by steady levels. Glucagon concentrations (not shown) fell by ϳ30% during the initial 100 min under both experimental conditions and remained steady thereafter until 180 min.
Glucose fluxes. The integrated rates of uptake and disposal of exogenous glucose for the 3-h infusion period are shown in Table 2 . Uptake (Eq. 4) was slightly, but significantly, higher in id than in iv experiments (74.8 Ϯ 0.9 vs. 70.6 Ϯ 1.0 g/3 h; P Ͻ 0.01) on account of the difference in exogenous glucose levels recorded at the end of the infusions (Fig. 3) . Whole body metabolic clearance rate was ϳ45% higher in id studies (83.7 Ϯ 2.7 vs. 57.8 Ϯ 3.9 l/3 h; P Ͻ 0.001). Glucose was equally distributed between glycolysis (Eq. 5) and storage (Eq. 6) under both experimental conditions ( Table 2 ). The net carbohydrate balance was very close to isotopically measured storage under both conditions. Exogenous glucose oxidation (Eq. 7) was similar in id and iv experiments (ϳ12 g/3 h) and considerably lower than total carbohydrate oxidation.
The time course of these parameters is depicted in Fig. 4 for the period t ϭ 20-180 min, during which intestinal absorption was shown to be very close to the rate of infusion (Fig. 2E ). All parameters rose during the first 2 h and tended to stabilize thereafter. During the ascending period, the rises in glucose uptake (as in the 2-3 H experiments) and in glycogen storage were slightly steeper for the id experiments on account of the smaller increase in exogenous glucose concentrations, but the difference with the iv experiments was not statistically significant. At steady state during the last hour of infusion, the average flux rates for id vs. iv studies were the following (in mg ⅐ kg Ϫ1 ⅐ min Endogenous glucose output was progressively inhibited, as indicated by the rise in the specific activity of circulating glucose, which attained ϳ90% that of infused glucose at the end of the infusions under both experimental conditions (Fig. 3) . This suggested that endogenous glucose output, to the exclusion of labeled glycogen recycling, accounted for ϳ10% of the rate of exogenous glucose infusion, i.e., ϳ0.6 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 . Energy expenditure. During id glucose infusion, energy expenditure increased, reached its peak at ϳ100 min, and then decreased slightly (Fig. 4) . A faster fall was observed after the infusion ended. The integrated increment over 180 min amounted to 24 Ϯ 1 kcal. A smaller delayed increase in energy expenditure was also observed after iv glucose, but it did not reach statistical significance (ϩ8 Ϯ 3 kcal over 3 h). The difference between the two integrated incremental values was highly significant (P Ͻ 0.005).
DISCUSSION
The lower glycemic and higher insulinemic responses observed after id than after iv glucose confirm the results of many other studies (e.g., Refs. 24 and 26). Because the 3-h glucose entries from endogenous and exogenous sources were comparable in the two experimental protocols, the difference in glucose levels must have been entirely due to the greater whole body metabolic clearance rate observed in the id experiments ( Table 2 ). Note that our experimental design does not permit separate quantification of splanchnic and peripheral glucose uptake. The increased clearance associated with the id administration was at least partly Values are means Ϯ SE, in g/3 h (except for the metabolic clearance rate, which is in 1/3 h) and are normalized for a body weight of 84 kg (average weight in group II). NS, not significant. Data are integrated over the 3-h glucose infusion period. due to the higher insulin response generally attributed to an incretin effect involving gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP1) (8, 22) . In the present study, the difference in insulin response to id vs. iv glucose was relatively modest and was observed only during the initial 80 min of infusion (Fig. 3) . It has been demonstrated (31) that the incretin effect is much less marked after id than after oral glucose, owing to a lesser stimulation of GLP1 but not of GIP secretion. The slightly higher lactate response observed in our id vs. iv experiments has already been documented and attributed to extra lactate produced by the gut (27) .
To our knowledge, this is the first study comparing id and iv glucose metabolism in humans. This comparison was made possible by the demonstration in the first part of the study, using [2- 3 H]glucose, that glucose absorption from a constant id infusion is both rapid and complete after a lag period of ϳ20 min (Fig. 2E) . The validity of this demonstration rests essentially on three assumptions. The first assumption is that the [2] [3] H]glucose taken up by the tissues is immediately phosphorylated and the 3 H transferred to water, so that the 3 H 2 O formation reflects tissue glucose uptake. The second assumption is that the metabolic 3 H 2 O generated in intracellular water is in rapid exchange with the extracellular water in which measurements are made. Both of these assumptions have been validated previously in humans (30) . It is likely that some 3 H is lost in the futile cycling between glucose and glucose 6-phosphate in the liver, but there is marked disagreement in the literature regarding the level of activity of this cycle in humans (2, 21) . Because the 3 H lost in this cycle is recovered as 3 H 2 O, it should not affect the calculation of intestinal absorption (Eq. 3), but it should lead to some overestimation of tissue uptake (Eq. 1) and of V eff (Eq. 2). According to our calculations, V eff accounted for ϳ18% of TBW at 20 min and rose slowly to ϳ29% at the end of the infusion, a figure in the accepted normal range for extracellular fluid (9) . The initial rise in V eff with time probably reflects the progressive access of infused glucose to more and more remote parts of the interstitial fluid. The third assumption is that the time course of V eff obtained from the iv experiments is also applicable to the id experiments. In favor of the validity of this assumption is the great similarity between the curves describing exogenous glucose tissue uptake in the id experiments with [2- 3 H]glucose (Fig. 2, top) and H]glucose (Fig. 4, top) respectively. Indeed, in the latter case, calculations of uptake (Eq. 4) were based on the V eff derived from the iv [2- 3 H]glucose experiments (Eq. 2).
The authors of several previous studies showed by either hepatic vein catheterization (10, 11) or dual oral-iv tracer glucose techniques (12, 19 ) that a significant amount of glucose absorbed by the gut is taken up at first pass by the splanchnic tissues and does not appear in the systemic circulation. Our observation that glucose administered id is rapidly and completely absorbed (Fig. 2E) does not contradict these data. In the [2] [3] H]glucose experiments, intestinal absorption was indeed calculated as the sum of the metabolized glucose ( 3 H 2 O production) and the pool of [2- 3 H]glucose present in V eff . Any glucose taken up by the splanchnic bed at first pass will obviously not appear in the systemic circulation, but its absorption from the intestinal lumen will nevertheless be computed in the form of 3 H 2 O originating from its splanchnic (hepatic) metabolism. Unlike the isotope studies in which a peripheral and an oral glucose tracer is used, our experimental design does not allow the quantification of first-pass splanchnic glucose uptake.
The existence of a short lag period before the rate of absorption becomes equivalent to that of infusion was only to be expected. It probably corresponds to the time needed for the intraluminal glucose to cover a sufficiently large area of duodenal mucosa to enable absorption to keep pace with the load presented. Unfortunately, no data are available on the maximal duodenal glucose absorption rates measured over well-defined segments of duodenum in humans with concentrated glucose solutions. Such information would have permitted estimation of the approximate length of duodenum participating in the absorption process under our experimental conditions. Whatever the duodenal length involved in our studies, the intraluminal glucose not absorbed by the end of the infusion must have been quite small in view of the fast decline in exogenous and total glucose concentrations observed after the infusions ended (Figs. 1 and 3 ). These conclusions are in agreement with the data recently published by Livesey et al. (23) , who measured the systemic appearance of intraduodenal glucose in humans and showed complete and rapid absorption for infusion rates of Յ8 mg ⅐ kg Ϫ1 ⅐ min
Ϫ1
. Interestingly, their data suggest that absorption capacities might be much lower in the more distal part of the intestine.
In the second series of our experiments (group II), designed to quantitate the uptake and pathways of exogenous glucose disposal, we observed that, during the final hour of infusion, when glucose fluxes were reasonably steady, the rates of uptake were comparable under the two experimental conditions and that the uptake was more or less equally divided between glycolysis and storage. A similar pattern was observed for the 3-h infusion period as a whole (Table 2) . Because identical values of V eff were used in the calculation of exogenous uptake in id and iv studies (Eq. 4), the possible overestimation of V eff mentioned before should not invalidate the comparison between the two infusion protocols. Note that mean basal carbohydrate and fat oxidations were virtually identical in both of the tests that the subjects underwent (Table 1) , indicating a similar degree of metabolic fast. This is important, because the initial nutritional status is a major factor controlling the balance between glycolysis and oxidation on the one hand and storage on the other after oral or iv glucose administration (13, 14) .
As mentioned earlier, our experimental design did not allow us to quantitate hepatic and peripheral glucose metabolism separately. In human physiology, it is commonly believed (7), but not universally admitted (27) , that orally administered glucose specifically enhances hepatic uptake and storage, in particular because of the higher portal vein levels of insulin and glucose associated with this route of administration. Several possibilities may account for the finding that the site of entry of glucose did not affect the whole body glucose balance under our experimental conditions. 1) Even if the id route of infusion preferentially promotes splanchnic (hepatic) glucose uptake, the effect may be quantitatively too small to be detected at whole body level. 2) Specific enhancement of hepatic uptake and storage after id glucose may have been compensated for by a decrease in peripheral (muscle) storage, with the whole body glucose balance remaining unchanged. In favor of this latter possibility are studies in dogs (1, 16) , which compared hepatic uptake of glucose given via the portal or a peripheral vein in normal, conscious animals maintained at basal insulin and glucagon levels and in which it was found that, when glucose is delivered intraportally, hepatic uptake is enhanced at the expense of skeletal muscle uptake and storage (16) . These effects were attributed to a "portal signal" triggered by the negative arterial-portal glucose concentration gradient associated with the oral or intraportal delivery of glucose. A similar effect was documented in rats (5). It is not known whether this is also the case in humans, in whom comparable experiments cannot be made in the absence of access to the portal vein. 3) Finally, it is possible that neither hepatic nor peripheral glucose uptake and storage is affected by the route of glucose administration. This possibility is supported by the isotopic experiments performed in humans by Radziuk (28) , which showed that the amounts of hepatic glycogen formed by the direct and indirect pathways are not significantly altered by the route of glucose delivery (28, 29) . This author pointed out (28) that portal vein glucose levels are probably similar after oral and iv glucose because peripheral glucose levels are higher during iv administration. A simple calculation indicates that this was probably also the case in our study. Indeed, the absolute rate of glucose infusion amounted to ϳ500 mg/min in group II. Assuming a portal vein blood flow of 1,100 ml/min (17), intestinal glucose absorption should raise the blood level in the portal vein by ϳ45 mg/dl (ϳ50 mg/dl for plasma), a value close to the difference of ϳ47 mg/dl observed between peripheral plasma glucose during id and iv infusion (Fig. 3) . In addition, because insulin levels were similar in id and iv studies during the final 80 min of infusion (Fig. 3) , it is likely that, during that period, the liver was exposed to comparable levels of both glucose and insulin and therefore handled glucose in a similar manner under both conditions. However, this interpretation should be made cautiously, because it does not take into account the possible interference of other potential regulators of hepatic glucose metabolism such as splanchnic blood flow or the portal signal already mentioned.
Exogenous glucose oxidation, calculated from 14 CO 2 production, did not differ according to the route of administration. Note that this rate of oxidation, even after correction for incomplete recovery of 14 CO 2 was much lower (ϳ12 g/3 h) than total carbohydrate oxidation, measured by indirect calorimetry (ϳ35 g/3 h). This may indicate either that unlabeled preexisting glycogen continues to be oxidized during the process of exogenous glucose storage (i.e., glycogen turnover) or that the coefficient used for correcting expired 14 CO 2 production for incomplete recovery was inappropriate, or both. It should be noted that the recovery factor used (32) is supposed to be applied to studies in which the labeled expired CO 2 produced by a glucose infusion has reached a steady state thanks to priming of the bicarbonate pool. This was not the case under our experimental conditions, in which a smaller, yet undetermined, recovery factor should probably be used.
The thermic effect of intraduodenal glucose measured over the 3 h of infusion (24 Ϯ 1 kcal) amounted to 8.5 Ϯ 0.5% of the caloric content of the glucose taken up, in agreement with published data (20) . This value was significantly higher than after iv glucose, even though the metabolic fluxes in the various pathways were identical. Splanchnic tissues seem to be involved in this difference as shown in a recent study (4); iv and oral (and probably id) glucose elicit extrasplanchnic thermogenic effects of similar magnitude, but during iv infusion, splanchnic O 2 consumption is reduced, whereas, during oral (and probably id) administration, it rises proportionally to the splanchnic blood flow.
In conclusion, during constant id infusions of glucose in humans for 180 min at a relatively high rate (6 mg ⅐ kg Ϫ1 ⅐ min
), intestinal absorption becomes equal to the rate of infusion after a lag period of ϳ20 min. Whole body glucose uptake, glycolysis, oxidation, and storage are comparable to those recorded during equivalent iv infusions into the peripheral circulation. Because the insulin and estimated portal vein glucose levels were similar during the final 80 min of both iv and id infusion, our results suggest that hepatic glucose storage (and therefore muscle glucose storage estimated as whole body minus liver storage) were not affected by the route of glucose administration.
